Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

UK Health Watchdog Backs Lung Cancer Drug From Roche

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/10/2012 | 01:16am CET

The U.K.'s health-care watchdog said in final draft guidance Thursday that it is recommending the use of Roche Holding AG's (ROG.VX) Tarceva as a treatment option for advanced-stage lung-cancer patients.

The National Institute for Health and Clinical Excellence, known as NICE, decides what medicines should be used in the U.K.'s publicly-funded National Health Service. It said the drug--whose chemical name is erlotinib--is a cost-effective use of NHS resources.

NICE, which has already recommended AstraZeneca PLC's (>> AstraZeneca plc) Iressa, or gefitinib, for non-small-cell lung cancer, said that while there isn't any trial data directly comparing the two drugs, clinical specialists say the drugs are "very similar and equally as effective."

"We are pleased to be able to recommend another treatment option for this stage of the disease," said NICE Director Carole Longson.

The watchdog said its decision to back the drug came after it requested more information about it from the Swiss drug maker.

Roche wasn't immediately available for comment.

NICE said the draft guidance is now with consultees, who have the opportunity to appeal against it.

-By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; [email protected]

Stocks mentioned in the article : AstraZeneca plc, AstraZeneca plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
01:04p ASTRAZENECA : US FDA Accepts Regulatory Submission for TAGRISSO (Osimertinib) in..
08:41aDJASTRAZENECA : Says Tagrisso Supplemental NDA Accepted by FDA
08:10a ASTRAZENECA : US FDA accepts regulatory submission for Tagrisso in 1st-line EGFR..
08:00a ASTRAZENECA : FDA accepts Tagrisso submission for 1st-line nsclc
12/15 ASTRAZENECA : to launch diabetes drug - Xigduo XR in FY18
12/14 ASTRAZENECA : Researchers' Work from AstraZeneca Focuses on Proglucagon (The acu..
12/14 ASTRAZENECA : Investigators at AstraZeneca Target Pharmacology (Systems Pharmaco..
12/14 ASTRAZENECA : Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic L..
12/14 ASTRAZENECA : Research Results from AstraZeneca Update Understanding of Molecula..
12/13 ASTRAZENECA : Mercia invests £350k in software to boost the quality of digital ..
More news
News from SeekingAlpha
06:36a FDA accepts AstraZeneca's marketing application for Tagrisso in first-line EG..
12/15 AstraZeneca (AZN) Investor Presentation - Slideshow
12/14 AstraZeneca (AZN) Investor Science Late-Stage Conference Call (Transcript)
12/11 AstraZeneca's acalabrutinib shows treatment effect in CLL studies; shares up ..
12/09 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 9, 2017
Financials ($)
Sales 2017 21 817 M
EBIT 2017 5 975 M
Net income 2017 2 283 M
Debt 2017 12 395 M
Yield 2017 4,20%
P/E ratio 2017 32,76
P/E ratio 2018 27,66
EV / Sales 2017 4,34x
EV / Sales 2018 4,34x
Capitalization 82 301 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 68,4 $
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA9.99%82 988
JOHNSON & JOHNSON23.65%382 722
PFIZER14.53%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.4.94%212 270
MERCK AND COMPANY-4.47%153 386